Understanding the Draft Guidance on Postmarketing Safety Reporting for Combination Products – An Interactive Analysis with FDA and Industry

Amgen

601 13th St NW

Washington, District of Columbia, USA, 20005-3807

Advanced therapies/cell and gene therapyAPIsBiologics/ biosimilars/ vaccinesBiotechnologyCombination products/companion diagnosticsCosmeticsDiagnostics/IVDsDigital health/SaMD/AIGenericsMedical DevicesNutritional/Natural HealthOTCOtherPharmaceuticals